Isomorphic Labs eyes more than $2B

Drug discovery is the domain here — and the stakes are huge. Making a new medicine is slow, expensive, and full of dead ends. AI has looked promising for years, but the gap has always been the same: can it move from impressive biology demos to actual drug programs that pharma companies will fund at scale? (bloomberg.com) That is why the latest Isomorphic Labs fundraising talks matter. The company, spun out of Google DeepMind, is in advanced discussions to raise more than $2 billion, with Thrive Capital expected to lead and Alphabet also participating. (storage.googleapis.com) ### What is Isomorphic Labs, exactly? Isomorphic Labs is DeepMind’s drug-discovery spinout, launched in 2021 and led by Demis Hassabis. (alphafold.com) The pitch is simple but ambitious — use frontier AI not just to predict protein shapes, but to help design actual drug candidates across different disease areas and drug types. The company says its internal platform is a unified AI drug design engine, not a single model. ### Why does the $2 billion figure stand out? Because this is not a seed round or even a normal late-stage biotech round. Isomorphic announced its first external funding only on March 31, 2025, raising $600 million from Thrive, GV, and Alphabet. (bloomberg.com) Jumping from that to talks for more than $2 billion barely a year later suggests investors think the company has moved from “interesting science bet” to “build this at pharma scale.” ### What changed to justify that? Part of it is momentum. Isomorphic has been stacking partnerships with major drugmakers. It started 2024 with Eli Lilly and Novartis collaborations, expanded the Novartis deal in February 2025, and added Johnson & Johnson in January 2026. (storage.googleapis.com) That matters because pharma companies do not sign up just for a cool model — they sign up if they think the platform can improve hit-finding, molecule design, or the odds of getting to clinic. ### Where does AlphaFold fit in? AlphaFold is the scientific foundation under all this. The public AlphaFold database now offers more than 200 million protein structure predictions, and AlphaFold 3 pushed beyond proteins to model interactions involving DNA, RNA, ligands, and other biomolecules. (storage.googleapis.com) Basically, AlphaFold helped turn structural biology from a bottleneck into something much more computable. Isomorphic is trying to turn that scientific advantage into a commercial drug engine. ### So is this just “AlphaFold, but monetized”? Not quite. Predicting structure is useful, but drug discovery needs more than that. You need to identify targets, design molecules, estimate binding, optimize for safety and potency, and then survive preclinical and clinical testing. (isomorphiclabs.com) The catch is that biology is messy. A model can narrow the search space a lot, but it still has to produce compounds that work in cells, animals, and eventually humans. That is why Isomorphic keeps pairing its software with pharma partners that can run the wet-lab and development side. ### Why are investors willing to fund this now? Because AI-for-science is starting to look like a real commercial category, not just a research flex. (alphafold.com) Isomorphic also has unusual credibility — DeepMind lineage, Hassabis at the top, AlphaFold 3 co-development, and backing from Alphabet. That lowers one big risk for investors: the company is unlikely to run out of compute, talent, or strategic support while it tries to prove the model in the clinic. ### What is the real milestone to watch? Human data. Hassabis has pointed to first-in-human trials by the end of 2026. That is the moment when this story stops being mostly about fundraising and platform quality and starts being about whether AI-designed drug programs can survive the harshest test in biotech. (storage.googleapis.com) ### Bottom line? The fundraising talks are big, but the deeper story is bigger. Isomorphic Labs is trying to turn one of AI’s clearest scientific wins into a full-stack drug company — and investors seem ready to finance that bet at a scale that looks a lot more like pharma than software. (bloomberg.com) (startuphub.ai) (storage.googleapis.com)